Literature DB >> 12907604

Decreased repair activities of 1,N(6)-ethenoadenine and 3,N(4)-ethenocytosine in lung adenocarcinoma patients.

Elzbieta Speina1, Maja Zielińska, Alain Barbin, Daniel Gackowski, Janusz Kowalewski, Maria A Graziewicz, Janusz A Siedlecki, Ryszard Oliński, Barbara Tudek.   

Abstract

To assess the role of oxidative stress and lipid peroxidation (LPO) in the pathogenesis of lung cancer, we measured the levels of 1,N(6)-ethenoadenine (epsilonA) and 3,N(4)-ethenocytosine (epsilonC) in the DNA by immunoaffinity/(32)P postlabeling (33 cases). We also measured the capacity for epsilonA and epsilonC repair (by the nicking assay) in normal and tumor lung tissues, as well as in blood leukocytes of lung cancer patients (56 cases). Repair activities for epsilonA and epsilonC were also assayed in leukocytes of healthy volunteers, matched with cancer patients for age, sex, and smoking habit (25 individuals). Up to 10-fold variations among individuals were observed both in adducts level and repair activities. No differences in epsilonA and epsilonC levels between tumor and nonaffected lung tissues were recorded. However, leukocytes accumulated a significantly higher number of DNA adducts than the lung tissues. Repair activities for both epsilonA and epsilonC were significantly higher in tumor than in normal lung tissue. No significant differences in epsilonA and epsilonC repair activities were associated with age, sex, or smoking habit. However, a significant difference in repair capacity was observed between two histological types of lung cancer, squamous cell carcinoma (SQ) and adenocarcinoma (AD). In individuals suffering from lung AD, epsilonA- and epsilonC-repair activities in normal lung and blood leukocytes were significantly lower than in SQ patients. Moreover, in nonaffected lung tissue of AD patients, the ratio epsilonA/epsilonC adducts was lower than in SQ patients. Differences have also been found between epsilonA and epsilonC repair activities of cancer patients and healthy volunteers. Repair capacity for epsilonA was significantly lower in blood leukocytes of lung cancer patients than in leukocytes of healthy volunteers (P = 0.012). This difference was even larger between healthy volunteers and patients developing inflammation-related AD (P = 0.00033). Repair activities for epsilonC were the same in leukocytes of healthy controls, all lung cancer patients, and SQ patients. However, individuals with ADs revealed significantly lower epsilonC-repair activity (P = 0.013). These results suggest that oxidative stress-mediated lipid peroxidation might contribute to induction and/or progression of lung cancer. Decreased activity of base excision repair pathway for epsilonA and epsilonC is associated particularly with inflammation-related lung AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907604

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Direct repair of 3,N(4)-ethenocytosine by the human ALKBH2 dioxygenase is blocked by the AAG/MPG glycosylase.

Authors:  Dragony Fu; Leona D Samson
Journal:  DNA Repair (Amst)       Date:  2011-11-11

2.  Benefits and risks of iron supplementation in anemic neonatal pigs.

Authors:  Paweł Lipinski; Rafał R Starzyński; François Canonne-Hergaux; Barbara Tudek; Ryszard Oliński; Paweł Kowalczyk; Tomasz Dziaman; Olivier Thibaudeau; Mikołaj A Gralak; Ewa Smuda; Jarosław Woliński; Agnieszka Usińska; Romuald Zabielski
Journal:  Am J Pathol       Date:  2010-09       Impact factor: 4.307

3.  Insights into the Direct Oxidative Repair of Etheno Lesions: MD and QM/MM Study on the Substrate Scope of ALKBH2 and AlkB.

Authors:  Stefan A P Lenz; Deyu Li; Stacey D Wetmore
Journal:  DNA Repair (Amst)       Date:  2020-09-09

4.  Involvement of oxidatively damaged DNA and repair in cancer development and aging.

Authors:  Barbara Tudek; Alicja Winczura; Justyna Janik; Agnieszka Siomek; Marek Foksinski; Ryszard Oliński
Journal:  Am J Transl Res       Date:  2010-05-15       Impact factor: 4.060

5.  Germ line variants of human N-methylpurine DNA glycosylase show impaired DNA repair activity and facilitate 1,N6-ethenoadenine-induced mutations.

Authors:  Sanjay Adhikari; Mahandranauth A Chetram; Jordan Woodrick; Partha S Mitra; Praveen V Manthena; Pooja Khatkar; Sivanesan Dakshanamurthy; Monica Dixon; Soumendra K Karmahapatra; Nikhil K Nuthalapati; Suhani Gupta; Ganga Narasimhan; Raja Mazumder; Christopher A Loffredo; Aykut Üren; Rabindra Roy
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

6.  Kinetic mechanism for the flipping and excision of 1,N(6)-ethenoadenine by human alkyladenine DNA glycosylase.

Authors:  Abigail E Wolfe; Patrick J O'Brien
Journal:  Biochemistry       Date:  2009-12-08       Impact factor: 3.162

7.  Slow repair of lipid peroxidation-induced DNA damage at p53 mutation hotspots in human cells caused by low turnover of a DNA glycosylase.

Authors:  Jordan Woodrick; Suhani Gupta; Pooja Khatkar; Sanchita Sarangi; Ganga Narasimhan; Akriti Trehan; Sanjay Adhikari; Rabindra Roy
Journal:  Nucleic Acids Res       Date:  2014-07-31       Impact factor: 16.971

8.  Metabolic Pathways and Networks Associated With Tobacco Use in Military Personnel.

Authors:  Dean P Jones; Douglas I Walker; Karan Uppal; Patricia Rohrbeck; Col Timothy M Mallon; Young-Mi Go
Journal:  J Occup Environ Med       Date:  2016-08       Impact factor: 2.162

9.  AlkB homologue 2-mediated repair of ethenoadenine lesions in mammalian DNA.

Authors:  Jeanette Ringvoll; Marivi N Moen; Line M Nordstrand; Lisiane B Meira; Bo Pang; Anders Bekkelund; Peter C Dedon; Svein Bjelland; Leona D Samson; Pål Ø Falnes; Arne Klungland
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

10.  Human RECQL5beta stimulates flap endonuclease 1.

Authors:  Elzbieta Speina; Lale Dawut; Mohammad Hedayati; Zhengming Wang; Alfred May; Sybille Schwendener; Pavel Janscak; Deborah L Croteau; Vilhelm A Bohr
Journal:  Nucleic Acids Res       Date:  2010-01-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.